Clinical trials

A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to;Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor;Activity of Mipasetamab Uzoptirine (ADCT-601) Monotherapy and in;Combination with Other Anti-Cancer Therapies in Patients with Selected;Advanced Solid Tumors.

A randomized, double-blind, multi-center, Phase III Study of AK112 or placebo combined with;pemetrexed and carboplatin in patients with EGFR-mutant locally advanced or metastatic nonsquamous;NSCLC who have failed to EGFR-TKI treatment.

Analysis of Circulating Tumor Markers in Blood

A Phase 2, Open-label, Multi-arm;Study of Tislelizumab in Combination With Investigational;Agents With or Without Chemotherapy in Patients With;Previously Untreated, Locally Advanced, Unresectable, or;Metastatic Non-Small Cell Lung Cancer.

A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard;dermatologic management on selected dermatologic adverse events among patients with locally;advanced or metastatic EGFR-mutated NSCLC treated first-line with;amivantamab + lazertinib.

A Phase II Study of the BRAF Inhibitor Encorafenib in Combination With the MEK Inhibitor Binimetinib in Patients With BRAFV600E-mutant Metastatic Non-small Cell Lung Cancer

68Ga-FAPI-46 PET/CT for predicting histological response;to neoadjuvant chemo-immunotherapy in triple-negative breast cancer.

First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1047 in Subjects With Malignant Solid Tumors.

A Phase 1, Multicentre, Open-label, Dose-escalation and Cohort Expansion Study of;Niraparib and Dostarlimab in Paediatric Patients with Recurrent or Refractory Solid Tumours

Multicentric randomized phase I/IIa trial of the safety and immunogenicity of a;therapeutic anti-HPV DC targeting vaccine in patients with Human papillomavirus;(HPV)-positive oropharyngeal cancer.